Ertapenem Sodium vs. Piperacillin/Tazobactam in the Treatment of Complicated Intra-Abdominal Infections (0826-037)

• Status: Completed
• Trial end date: 2004-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to compare the efficacy of ertapenem and piperacillin/tazobactam with respect to the clinical response in baseline microbiologically evaluable patients; and to evaluate the tolerability and safety of ertapenem compared to piperacillin/tazobactam.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Ertapenem; Penicillanic Acid; Piperacillin; Piperacillin, tazobactam drug combination; Tazobactam

Criteria

Inclusion Criteria:

• Male or female patients (greater or equal to 18 years of age)

• Intraoperative/Postoperative Enrollment: Upon visual confirmation of an intra-abdominal infection.

• Preoperative Enrollment: Patients may be enrolled preoperatively if they meet certain criteria

Exclusion Criteria:

• Failure to meet all inclusion criteria.

• Patients who are considered unlikely to survive the 6-8 week study period.

• Pregnant or nursing women, or fertile women not practicing adequate methods of contraception.